OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer

January 31st 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses a trial investigating sacituzumab govitecan for patients with triple-negative breast cancer (TNBC).

Dr. Oh on Abiraterone Versus Docetaxel in Prostate Cancer

January 31st 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.

Dr. Perales on Treatment With Approved CAR T-Cell Therapy

January 31st 2018

Miguel-Angel Perales, MD, Deputy Chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses determining which chimeric antigen receptor (CAR) T-cell therapy to use for patients with hematologic malignancies.

Dr. Massarelli on First-Line ALK+ NSCLC Treatment

January 30th 2018

Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Wang Discusses Crenolanib Plus Chemotherapy in AML

January 30th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia.

Dr. Kardosh Discusses Epacadostat in Gastric/GEJ Adenocarcinoma

January 30th 2018

Adel Kardosh, MD, postdoctoral medical fellow, oncology, Stanford Medicine, discusses epacadostat in gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Carey Discusses the CALGB40502 Trial in TNBC

January 30th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC).

Dr. Wise on the Development of Precision Medicine in Prostate Cancer

January 30th 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.

Dr. King on Role of Sentinel Lymph Node Biopsy in Breast Cancer

January 30th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses the role of sentinel lymph node biopsy in breast cancer.

Dr. Zhu Discusses Findings of the KEYNOTE-224 in HCC

January 30th 2018

Andrew Zhu, MD, PhD, director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the findings of KEYNOTE-224 in hepatocellular carcinoma (HCC).

Dr. Skarbnik on Impact of Checkpoint Inhibition Following ASCT

January 30th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses the preliminary safety and efficacy data for checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplantation in high-risk hematologic malignancies.

Dr. Balar on Current and Future Standards of Care in Kidney Cancer Treatment

January 30th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.

Dr. Coleman on the Role of Ramucirumab in Gynecologic Cancer

January 30th 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of ramucirumab (Cyramza) in patients with gynecologic cancer.

Dr. Goetz on the MONARCH Trials for Breast Cancer

January 30th 2018

Matthew P. Goetz, MD, professor of oncology and pharmacology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the MONARCH trials for patients with breast cancer.

Dr. Karasic on Palbociclib in Esophageal and Gastric Cancer

January 30th 2018

Thomas Karasic, MD, investigator at Penn Medicine, discusses the rationale behind the phase II trial (NCT01037790) of palbociclib (Ibrance) in patients with advanced esophageal or gastric cancer.

Dr. Taneja Discusses Imaging Techniques Used to Detect Metastatic Prostate Cancer

January 27th 2018

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses a number of emerging imaging techniques used to stage prostate cancer.

Dr. Goy Discusses Combinations in Mantle Cell Lymphoma

January 27th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combinations in mantle cell lymphoma.

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma

January 27th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.

Dr. Huang Discusses Robotic Surgery for Bladder Cancer

January 27th 2018

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses robotic surgery in the treatment of bladder cancer.

Dr. Wysock on Robotic Approaches in Cytoreductive Nephrectomy

January 27th 2018

James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the placement of novel robotic and minimally invasive approaches in nephrectomy.